Plexāā, a UK-based MedTech startup, closes $4.5M funding extension round led by TCP Health Ventures to bring its BLOOM⁴³ medical device for breast surgery to the U.S.
The funding includes investments from existing and new investors, i4i grant funding, and support from Thena Capital, a London-based VC firm focused on digital health.
BLOOM⁴³ is a wearable device for breast cancer surgery utilizing Supraphysiological Preconditioning to reduce complication rates and improve surgical readiness.
Plexāā aims to make prehabilitation and preconditioning the standard of care for surgery, expand to other surgical fields, and enhance patient outcomes globally.